GNCA stock plunges 97% to $0.0001 on NASDAQ 09 Jan 2026: key risk signal
GNCA stock dropped to $0.0001 intraday, down 97.44%, putting Genocea Biosciences, Inc. (GNCA) on the top losers list on NASDAQ in the United States. We track the move with volume of 30,268 shares versus a 50-day average of 80,568. This sharp fall follows Chapter 11 reorganization and thin liquidity, and it changes short-term risk and valuation dynamics for investors.
GNCA stock: intraday price action and core metrics
GNCA stock traded between $0.0001 and $0.0001 today on NASDAQ with a last price of $0.0001. The stock opened at $0.0007 and the previous close was $0.0039, showing extreme intraday weakness. Volume hit 30,268 versus an average volume of 80,568, signaling lower-than-normal liquidity.
Why GNCA stock fell: news, bankruptcy and clinical updates
Genocea filed Chapter 11 in 2022 and limited operating news has followed, which keeps downside pressure on GNCA stock. The company’s lead programs, GEN-009 and GEN-011, are early stage and provide no near-term revenue, increasing sensitivity to capital events. With market cap listed as 0 and scarce trading interest, any negative headline can drive outsized moves.
Balance sheet and valuation snapshot for GNCA stock
Key per-share metrics show cash per share $0.54 and book value per share $0.39, while revenue per share TTM is $0.02. The current ratio is 2.24 and debt to equity is 0.41, giving modest short-term liquidity. Market pricing implies effectively zero market cap and a price-to-book ratio near 0.00, reflecting deep market discounting.
Technical and trading context for GNCA stock
Price averages show a 50-day average of $0.0047 and a 200-day average of $0.1146, highlighting a long-term downtrend. GNCA stock sits at year low $0.0001 versus a year high $1.45, which emphasizes extreme volatility. We note relative volume 0.38, suggesting today’s move is meaningful but not a full liquidity flush.
Meyka AI grade and model view on GNCA stock
Meyka AI rates GNCA with a score of 62.75 out of 100 — Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI notes the stock’s high downside risk from low liquidity and limited revenue, tempered by positive working capital and cash per share. These grades are not guarantees and we are not financial advisors.
Risk drivers and what to watch in GNCA stock
Watch cash runway, Chapter 11 developments, and any clinical readouts for GEN-009 or GEN-011, as binary events can swing GNCA stock sharply. Secondary risks include delisting from NASDAQ and further share dilution if financing is required. Monitor average volume, bid-ask spreads and regulatory filings for near-term clarity.
Final Thoughts
Key takeaways: GNCA stock trades at $0.0001 on NASDAQ as an intraday top loser, driven by legacy bankruptcy proceedings, minimal liquidity and no current revenue. Meyka AI’s forecast model projects a 12-month fair value of $0.0002, implying an upside of 100.00% versus the current price of $0.0001; forecasts are model-based projections and not guarantees. Our analysis highlights short-term downside risk from thin trading, but a small modeled upside if clinical or restructuring outcomes improve. For traders, GNCA stock is speculative and volatile; for longer-term holders, watch cash runway and reorganization milestones before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform insight, not investment advice.
FAQs
What caused GNCA stock to drop today?
GNCA stock fell on thin liquidity and legacy Chapter 11 restructuring risks. Low volume and lack of revenue amplify moves, so any negative update or technical selling can trigger big percentage losses.
Is GNCA stock a buy after the drop?
GNCA stock is highly speculative. Our grade is B/HOLD and the Meyka model projects $0.0002 in 12 months. Investors should wait for clearer cash runway or clinical progress before buying.
What key metrics should I monitor for GNCA stock?
Track cash per share ($0.54), current ratio (2.24), filings on Chapter 11, trading volume relative to the 50-day average, and any clinical readouts for GEN-009 or GEN-011.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
